335 related articles for article (PubMed ID: 35977284)
21. Racial Inequality in Receipt of Medications for Opioid Use Disorder.
Barnett ML; Meara E; Lewinson T; Hardy B; Chyn D; Onsando M; Huskamp HA; Mehrotra A; Morden NE
N Engl J Med; 2023 May; 388(19):1779-1789. PubMed ID: 37163624
[TBL] [Abstract][Full Text] [Related]
22. Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States.
Goedel WC; Shapiro A; Cerdá M; Tsai JW; Hadland SE; Marshall BDL
JAMA Netw Open; 2020 Apr; 3(4):e203711. PubMed ID: 32320038
[TBL] [Abstract][Full Text] [Related]
23. Telehealth Initiation of Buprenorphine for Opioid Use Disorder: Patient Characteristics and Outcomes.
Nguyen B; Zhao C; Bailly E; Chi W
J Gen Intern Med; 2024 Jan; 39(1):95-102. PubMed ID: 37670069
[TBL] [Abstract][Full Text] [Related]
24. Overall and Telehealth Addiction Treatment Utilization by Age, Race, Ethnicity, and Socioeconomic Status in California After COVID-19 Policy Changes.
Palzes VA; Chi FW; Metz VE; Sterling S; Asyyed A; Ridout KK; Campbell CI
JAMA Health Forum; 2023 May; 4(5):e231018. PubMed ID: 37204804
[TBL] [Abstract][Full Text] [Related]
25. Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder.
Williams AR; Samples H; Crystal S; Olfson M
Am J Psychiatry; 2020 Feb; 177(2):117-124. PubMed ID: 31786933
[TBL] [Abstract][Full Text] [Related]
26. Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes.
Bovell-Ammon BJ; Yan S; Dunn D; Evans EA; Friedmann PD; Walley AY; LaRochelle MR
JAMA Netw Open; 2024 Mar; 7(3):e242732. PubMed ID: 38497959
[TBL] [Abstract][Full Text] [Related]
27. Association of Race and Ethnicity and Medicare Program Type With Ambulatory Care Access and Quality Measures.
Johnston KJ; Hammond G; Meyers DJ; Joynt Maddox KE
JAMA; 2021 Aug; 326(7):628-636. PubMed ID: 34402828
[TBL] [Abstract][Full Text] [Related]
28. Patient and Community Factors Affecting Treatment Access for Opioid Use Disorder.
Bulgin D; Patrick SW; McElroy T; McNeer E; Dupont WD; Murry VM
Obstet Gynecol; 2023 Aug; 142(2):339-349. PubMed ID: 37473410
[TBL] [Abstract][Full Text] [Related]
29. Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic.
Frost MC; Zhang L; Kim HM; Lin LA
JAMA Netw Open; 2022 Oct; 5(10):e2236298. PubMed ID: 36223118
[TBL] [Abstract][Full Text] [Related]
30. Urine Drug Screening in a Telehealth Setting for the Treatment of Opioid Use Disorder.
Williams AR; Rowe C; Gallagher R; Aronowitz SV; Diamond-Reivich J; Bisaga A
JAMA Health Forum; 2023 Jul; 4(7):e232247. PubMed ID: 37505489
[TBL] [Abstract][Full Text] [Related]
31. Trends in Medicaid Enrollment and Disenrollment During the Early Phase of the COVID-19 Pandemic in Wisconsin.
Dague L; Badaracco N; DeLeire T; Sydnor J; Tilhou AS; Friedsam D
JAMA Health Forum; 2022 Feb; 3(2):e214752. PubMed ID: 35977274
[TBL] [Abstract][Full Text] [Related]
32. Access to Medications for Opioid Use Disorder During COVID-19: Retrospective Study of Commercially Insured Patients from 2019-2022.
Rajagopal S; Westra J; Raji MA; Wilkes D; Kuo YF
Am J Prev Med; 2024 Apr; 66(4):635-644. PubMed ID: 37979624
[TBL] [Abstract][Full Text] [Related]
33. A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic.
Cunningham CO; Khalid L; Deng Y; Torres-Lockhart K; Masyukova M; Thomas S; Zhang C; Lu T
J Subst Abuse Treat; 2022 Apr; 135():108641. PubMed ID: 34863608
[TBL] [Abstract][Full Text] [Related]
34. Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts.
Schiff DM; Nielsen T; Hoeppner BB; Terplan M; Hansen H; Bernson D; Diop H; Bharel M; Krans EE; Selk S; Kelly JF; Wilens TE; Taveras EM
JAMA Netw Open; 2020 May; 3(5):e205734. PubMed ID: 32453384
[TBL] [Abstract][Full Text] [Related]
35. Treatment of Opioid Use Disorder With Buprenorphine Among US Adolescents and Young Adults During the Early COVID-19 Pandemic.
Alinsky RH; Prichett L; Chang HY; Alexander GC; Stein BD; Saloner B
J Adolesc Health; 2022 Aug; 71(2):239-241. PubMed ID: 35595609
[TBL] [Abstract][Full Text] [Related]
36. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
[TBL] [Abstract][Full Text] [Related]
37. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
[TBL] [Abstract][Full Text] [Related]
38. Emergency Department Access to Buprenorphine for Opioid Use Disorder.
Herring AA; Rosen AD; Samuels EA; Lin C; Speener M; Kaleekal J; Shoptaw SJ; Moulin AK; Campbell A; Anderson E; Kalmin MM
JAMA Netw Open; 2024 Jan; 7(1):e2353771. PubMed ID: 38285444
[TBL] [Abstract][Full Text] [Related]
39. Gabapentin Use Among Individuals Initiating Buprenorphine Treatment for Opioid Use Disorder.
Ellis MS; Xu KY; Tardelli VS; Fidalgo TM; Buttram ME; Grucza RA
JAMA Psychiatry; 2023 Dec; 80(12):1269-1276. PubMed ID: 37672238
[TBL] [Abstract][Full Text] [Related]
40. Urine drug testing among Medicaid enrollees initiating buprenorphine treatment for opioid use disorder within 9 MODRN states.
Hammerslag L; Talbert J; Donohue JM; Sharbaugh M; Ahrens K; Allen L; Austin AE; Gordon AJ; Jarlenski M; Kim JY; Mohamoud S; Tang L; Burns M;
Drug Alcohol Depend; 2023 Sep; 250():110875. PubMed ID: 37413960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
